Research Analysts Set Expectations for NeuroPace Q2 Earnings

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Analysts at Leerink Partnrs raised their Q2 2025 EPS estimates for NeuroPace in a note issued to investors on Wednesday, June 4th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings of ($0.22) per share for the quarter, up from their previous estimate of ($0.23). The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace's Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.40) EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.46 EPS.

NeuroPace (NASDAQ:NPCE - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. The firm had revenue of $22.52 million for the quarter, compared to analyst estimates of $21.85 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%.

Other analysts also recently issued reports about the stock. JPMorgan Chase & Co. increased their price target on shares of NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a report on Wednesday, May 14th. Cantor Fitzgerald restated an "overweight" rating and set a $17.00 target price on shares of NeuroPace in a research report on Wednesday, May 14th. Finally, HC Wainwright started coverage on NeuroPace in a report on Wednesday, May 28th. They issued a "buy" rating and a $18.00 price target for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, NeuroPace currently has an average rating of "Moderate Buy" and an average price target of $15.50.

NeuroPace Stock Performance

Shares of NPCE stock traded down $0.60 on Monday, hitting $11.23. The company had a trading volume of 331,187 shares, compared to its average volume of 167,018. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.98. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. The firm has a market cap of $368.33 million, a P/E ratio of -11.23 and a beta of 2.03. The company has a 50-day moving average price of $12.89 and a 200-day moving average price of $12.37.

Insider Activity

In related news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total transaction of $2,664,955.60. Following the completion of the transaction, the insider now owns 3,238,199 shares in the company, valued at $51,325,454.15. This represents a 4.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 22.20% of the company's stock.

Institutional Investors Weigh In On NeuroPace

Large investors have recently bought and sold shares of the company. Rhumbline Advisers increased its position in shares of NeuroPace by 15.2% during the first quarter. Rhumbline Advisers now owns 17,227 shares of the company's stock worth $212,000 after purchasing an additional 2,267 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in NeuroPace by 54.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock valued at $73,000 after purchasing an additional 2,279 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in NeuroPace during the 4th quarter worth $29,000. Charles Schwab Investment Management Inc. grew its holdings in shares of NeuroPace by 7.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 39,237 shares of the company's stock worth $482,000 after buying an additional 2,700 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new stake in shares of NeuroPace in the first quarter valued at about $53,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.